JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Volume 27, Number 4, 2011
© Mary Ann Liebert, Inc.
DOI: 10.1089/jop.2010.0194

# Effects of Intravitreally Injected Bevacizumab on Vascular Endothelial Growth Factor in Fellow Eyes

Kayako Matsuyama,[1] Nahoko Ogata,[2] Masato Matsuoka,[1] Mitsumasa Wada,[1]
Tetsuya Nishimura,[1] and Kanji Takahashi[3]

## Abstract

***Purpose:*** Whether an intravitreal injection of bevacizumab in 1 eye will have any effect on the fellow eye has been discussed. The aim of this study was to determine the level of vascular endothelial growth factor (VEGF) in the fellow eyes after an intravitreal injection of bevacizumab in 1 eye with proliferative diabetic retinopathy.
***Methods:*** Eight patients who had similar findings of proliferative diabetic retinopathy in both eyes were studied. Four patients had rubeosis (rubeosis group), and 4 patients did not have rubeosis (no-rubeosis group) in the anterior chamber. All patients received an intravitreal injection of bevacizumab (1.25 mg) in 1 eye. Samples of aqueous humor were collected from the injected eyes just before the injection of bevacizumab and 1 day after the first injection just before vitrectomy. Samples of aqueous humor from the fellow eyes were collected just before a second injection of bevacizumab in the fellow eye at 7 days after the first injection. The concentration of VEGF in the aqueous humor was measured by enzyme-linked immunosorbent assay.
***Results:*** After 1 day, the concentration of VEGF in injected eyes was significantly reduced from 3,230.3 ± 2,136.8 to 3.1 ± 3.6 pg/mL ($P < 0.05$) in eyes with rubeosis and 465.0 ± 78.8 to 0 pg/mL ($P < 0.05$) in those without rubeosis. After 7 days, the VEGF level of the fellow eyes was still significantly lower than that in the injected eye just before the injection of bevacizumab (688.5 ± 443.1 pg/mL) in the rubeosis group, and it was 7.8 ± 13.2 pg/mL in the no-rubeosis group ($P < 0.05$).
***Conclusions:*** A single intravitreal injection of bevacizumab significantly reduced the VEGF concentrations in the aqueous humor of the fellow untreated eye. Thus, we need to be observant of the fellow eyes after a unilateral injection and also examine the patients for systemic changes.

## Introduction

VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) plays a key role in the development of human eye diseases characterized by neovascularizations, for example, proliferative diabetic retinopathy (PDR). Because the level of VEGF in the vitreous is highly correlated with the severity of diabetic retinopathy,[1,2] intravitral bevacizumab (Avastin; Genentech, Inc., San Francisco, CA), a recombinant human monoclonal IgG1 antibody that binds to all isoforms of human VEGF, has been used to treat PDR. Although bevacizumab has been approved by the United States Food and Drug Administration for intravenous use for metastatic colorectal cancer, its beneficial effects on eyes with neovascular age-related macular degeneration,[3] diabetic retinopathy,[4] and retinal vein occlusion have been reported.[5] Intravitreal bevacizumab has been shown to lead to a significant decrease in the VEGF levels in the aqueous of patients with diabetic retinopathy.[6–8]

However, warnings have been published on adverse systemic complications of bevacizumab.[9,10] This is relevant, because we have shown that the blood level of VEGF is decreased after an intravitreal injection of bevacizumab, which indicated that an effective concentration of bevacizumab had entered the general circulation.[11] The question then arises whether an intravitreal injection of bevacizumab in 1 eye will have any effect on the VEGF level in the fellow eye.

Avery et al. reported that some patients with bilateral PDR had a regression of neovascularization in both eyes when bevacizumab was intravitreally injected in only 1 eye.[4] Yoon et al. described the rapid progression of subclinical age-related macular degeneration in an untreated fellow eye after

[1]Department of Ophthalmology, Kansai Medical University, Takii Hospital, Osaka, Japan.
[2]Department of Ophthalmology, Nara Medical University, Nara, Japan.
[3]Department of Ophthalmology, Kansai Medical University, Hirakata Hospital, Osaka, Japan.

intravitreal bevacizumab[6] and Sawada et al. reported that, after a unilateral intravitreal injection of bevacizumab in eye with diabetic retinopathy, the VEGF concentration in the aqueous humor of the contralateral eye was not decreased at 7 days after the first injection.[7] A recent study reported that there were no pharmacological indications for a significant concentration of unbound bevacizumab.[8] Whether an intravitreal injection of bevacizumab in 1 eye will have any effect on the fellow eye remains undetermined.

Thus, the purpose of this study was to determine the level of VEGF in the fellow eyes of patients with diabetic retinopathy who had received an intravitreal injection of bevacizumab in 1 eye.

## Methods

### Subjects

The procedures used in this study conformed to tenets of the Declaration of Helsinki and were performed after receiving approval from the Institutional Review Committee of Kansai Medical University. An informed consent was obtained from all patients. Patients with aggressive PDR were studied.

Sixteen eyes of 8 patients with type 2 diabetes mellitus (age range: 44–68, average: 55.8 years) were studied (clinical data of patients are shown in Table 1). The clinical findings of PDR were very similar in both eyes of all patients. Of the 8 patients, 4 patients had aggressive PDR with rubeosis of the iris and/or angle structures (rubeosis group, cases 1–4 in Table 1) and 4 patients did not have rubeosis of the iris and angle structures (no-rubeosis group, cases 5–8 in Table 1). The clinical findings indicated that all patients would benefit from vitrectomy, and all received an intravitreal injection of bevacizumab as a preoperative adjunctive therapy. Because the clinical findings of PDR were similar in both eyes of all patients, the first treated eye was selected by the visual acuity, severity of vitreous hemorrhage, and the intraocular pressure. Otherwise, the right eye was selected if these clinical data were all the same.

### Injection technique

The intravitreal injection of bevacizumab was performed as previously described in detail.[11–14] Briefly, under sterile conditions in the operating room, 1.25 mg/0.05 mL of bevacizumab (Avastin) was injected into the vitreous by a 30-gauge needle that was inserted into the eye 4.0 mm posterior to the limbus. The needle was carefully removed, and a sterile cotton applicator was used to prevent reflux. The postoperative medications included topical antibiotics 4 times/day. Vitrectomy was performed on the following day.

### Collecting ocular samples

All patients received an intravitreal injection of bevacizumab (1.25 mg) in 1 eye and underwent vitrectomy on the following day. The fellow eye received an intravitreal injection of bevacizumab at 7 days after the first injection of bevacizumab.

Samples of the aqueous humor were collected from the first eye just before the injection of bevacizumab and 1 day after the injection just before the vitrectomy. The samples of the aqueous humor from the fellow eyes were collected at

Table 1. Clinical Data of the Patients

| Case | Age | Sex | Severity of DR, ETDRS severity scale[20] (right eye) | Severity of DR, ETDRS severity scale (left eye) | First eye | Treatment after the injection of bevacizumab | Concentration of VEGF before the injection (pg/mL) | Concentration of VEGF at 1 day after the injection (pg/mL) | Rubeosis after the injection | Concentration of VEGF in the fellow eye (pg/mL) | Rubeosis of the fellow eye after the injection |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 59 | M | 75 | 75 | R | PPV+PC | 568.0 | 0 | — | 0 | — |
| 2 | 44 | M | 71 | 71 | R | PPV+PEA+IOL+PC | 376.0 | 0 | — | 0 | — |
| 3 | 59 | M | 71 | 71 | R | PPV+PEA+IOL+PC | 456.0 | 0 | — | 1.5 | — |
| 4 | 55 | F | 75 | 71 | R | PPV+PEA+IOL+PC | 460.2 | 0 | — | 29.7 | — |
| 5 | 68 | F | 85 | 85 | R | PPV+PEA+IOL+PC | 1,248.5 | 6.3 | Not detectable | 89.1 | Remain unchanged |
| 6 | 48 | M | 81 | 85 | L | PPV+PEA+IOL+PC | 1,849.9 | 6.2 | Not detectable | 628.2 | NVR was decreased |
| 7 | 54 | M | 81 | 85 | L | PPV+PEA+IOL+PC | 5,963.0 | 0 | Decreased | 953.6 | NVD was decreased |
| 8 | 59 | F | 81 | 81 | R | PPV+PC+SO | 3,859.8 | 0 | Decreased | 1,083.3 | Remain unchanged |

Cases 1–4: Rubeosis(−) group; cases 5–8: Rubeosis(+) group.
DR, diabetic retinopathy; ETDRS, early treatment diabetic retinopathy study; VEGF, vascular endothelial growth factor; PPV, pars plana vitrectomy; PEA, phacoemulsification and aspiration; IOL, intraocular lens implantation; PC, photocoagulation; NVD, neovascularization from the disc; NVR, neovascularization from the retina; SO, silicon oil injection.




**FIG. 1.** Flow chart of the experimental protocol. Bevacizumab (1.25 mg/mL) was injected into the vitreous cavity of the first eye as a preoperative adjunctive therapy. Samples of the aqueous humor from the injected eyes (first eyes) were collected just before the injection of bevacizumab and at 1 day after the injection just before the vitrectomy. The samples of the aqueous humor from the fellow eyes were collected at 7 days after the first injection just before the injection of bevacizumab.




**FIG. 2.** VEGF concentration in the aqueous humor before the injection. Mean VEGF concentration in the aqueous humor was 465.0±78.8 pg/mL (mean±standard deviation; range: 376–568 pg/mL) in the rubeosis group and 3,230.3±2,136.8 pg/mL (range: 1,248.5–5,963.0 pg/mL) in the no-rubeosis group. The higher level of VEGF in the rubeosis group is significant (*$P < 0.05$). VEGF, vascular endothelial growth factor.

7 days after the first injection just before the injection of bevacizumab (Fig. 1). All samples were collected in tubes containing EDTA and were immediately placed on ice and stored at −80°C before use.

### VEGF assay

The samples were thawed on ice, and the concentration of VEGF in the plasma was determined with an ELISA Kit (Quantikine® VEGF ELISA Kit; R&D Systems, Inc., Minneapolis, MN) according to the manufacturer's instructions. This assay employs a quantitative sandwich enzyme immunoassay technique. The concentrations of VEGF were determined by measuring the absorbance at 450 nm with a microplate reader (Titertek, Multiscan; Flow Laboratories, Inc., Helsinki, Finland), and the values were obtained from a standard curve that was determined with standard dilutions (range: 0–2,000 pg/mL). The background absorbance was subtracted from all values.

### Statistical analyses

Results are expressed as the means±standard deviation, and the significance of any differences was determined by repeated-measure analysis of variance by ranks with Dunn's multiple comparison test. A $P$ value of $<0.05$ was accepted as significant.

## Results

### Injected eyes

The mean VEGF concentration in the aqueous humor was 465.0±78.8 pg/mL (mean±standard deviation; range: 376–568 pg/mL) in the no-rubeosis group and 3,230.3±2,136.8 pg/mL (range: 1,248.5–5,963.0 pg/mL) in the rubeosis group. The higher level in the rubeosis group was highly significant ($P < 0.05$; Fig. 2). After 1 day, the VEGF concentration of the injected eyes significantly decreased to 0 pg/mL ($P < 0.05$; Fig. 3) in the no-rubeosis group and to 3.1±3.6 pg/mL with a range of 0–6.27 pg/mL in the rubeosis group ($P < 0.05$; Fig. 4). The decrease of ocular neovascularization was observed in all eyes at 1 day after the injection.

### Fellow eyes

Seven days later, the average VEGF level in the no-rubeosis group was 7.8±13.2 pg/mL with a range of 0–29.7 pg/mL, which was significantly lower than the pre-injection level of the first eye ($P < 0.05$; Fig. 3). In the rubeosis group, the average VEGF level in the rubeosis group was 688.5±443.1 pg/mL with a range of 89.1–1,083.2 pg/mL ($P < 0.05$; Fig. 4). This was also significantly lower than the




**FIG. 3.** No-rubeosis group. The VEGF concentration of the injected eyes significantly decreased to 0 pg/mL (*$P < 0.05$) after 1 day. After 7 days, the VEGF levels of fellow eyes (7.8±13.2 pg/mL) were significantly lower than that before the injection in the first eye (*$P < 0.05$).




**FIG. 4.** Rubeosis group. The VEGF concentration of injected eyes significantly decreased to 3.1±3.6 pg/mL with a range of 0–6.27 pg/mL ($P<0.05$) after 1 day. It was 688.5±443.1 pg/mL with a range of 89.1–1,083.2 pg/mL after 7 days in the fellow eyes. The VEGF levels in the aqueous humor of fellow eyes were significantly lower than that before the injection in the first eye (*$P<0.05$).

preinjection level of the first eye. The decrease of retinal neovascularization was observed in cases 4, 6, and 7 and the decrease of rubeosis was observed in cases 6 and 7.

## Discussion

The mean VEGF concentration in the aqueous humor in the eyes with rubeosis was significantly higher than that in the no-rubeosis eyes. This is in agreement with the higher VEGF level in the aqueous humor, which is significantly correlated with the VEGF level in the vitreous and the vitreous level of VEGF is correlated with the severity of diabetic retinopathy and the activity of the PDR.[1,2]

With the increasing use of bevacizumab for VEGF-mediated eye diseases, it is important to know the adverse systemic effects of intravitreal injection. Although experimental data on primates suggested that the full-length antibody might not penetrate the internal limiting membrane of the retina,[15] recent studies have shown that the full-length antibody did penetrate into the rabbit[16] and monkey retinas[17] within 24 hours. In addition, we have shown that the blood level of VEGF was markedly reduced as early as 1 day after the intravireal injection of bevacizumab and it was significantly lower than that of the initial level for as long as 1 month.[11] These results indicated that bevacizumab injected into the vitreous cavity enters the general circulation, where it acts to decrease the level of free VEGF rapidly and the effects lasted for at least 1 month.

Whether an intravitreal injection of bevacizumab in 1 eye will have any effect on the fellow eye has been discussed,[6–8] but it remains undetermined. Miyake et al. examined the effects of an intravitreal injection of bevacizumab in monkey eyes and reported that the aqueous VEGF concentrations in the fellow eyes did not change throughout the experiment.[18] However, they used only 3 normal monkeys. It is known that the VEGF levels in the blood and eyes are quite different in diabetics and normal individuals. Because they used normal monkeys without diabetes, they might not have detected significant differences in the VEGF levels. They also measured aqueous bevacizumab concentrations and reported that it peaked at 3 days, although the levels were low.[18] Even in normal animals, bevacizumab injected into the vitreous was detected in the untreated eye. Thus, it is quite possible that higher levels of aqueous bevacizumab concentrations would be detected in the fellow eyes with diabetic retinopathy because of the higher permeability of the vessels.

The VEGF concentrations in the aqueous humor of the fellow untreated eyes were significantly decreased at 7 days after the injection of bevacizumab, compared with the initial levels of the first eyes both in the no-rubeosis group and the rubeosis group.

Because we did not measure the VEGF concentration in the aqueous humor of the fellow eyes before the injection of bevacizumab into the first eye, we do not know the exact decrease of VEGF concentrations in the fellow untreated eye. However, we selected the patients who had similar clinical findings of PDR in both eyes. Thus, it is quite reasonable to consider that both eyes would have similar VEGF concentrations in the aqueous humor before the first injection of bevacizumab. Therefore, the low level of VEGF in the aqueous humor of the fellow untreated eyes indicates that bevacizumab injected into the vitreous cavity entered the general circulation rapidly and entered the fellow untreated eyes.

In addition, Avery et al. reported that some patients with bilateral PDR had a regression of neovascularization in both eyes when bevacizumab was intravitreally injected in only 1 eye.[4] Our findings support their observations. Intravitreally injected bevacizumab can pass into the general blood circulation and enter the fellow eyes and then can regress neovascularization.

Recently, the adverse systemic complication events after bevacizumab have been discussed,[9,10,19] and the elevation of blood pressure, severe gastrointestinal bleeding leading to hypotension, and myocardial ischemia have been reported.[10,19] A single intravitreal injection of bevacizumab 1.25 mg/0.05 mL was enough to reduce the VEGF levels significantly in the blood[11] and also affects the fellow untreated eye. We do not know how much of the intravitreally injected bevacizumab passes through the eye to the general circulation in patients with diabetic retinopathy. Thus, we need to be more careful about adverse systemic events. Further studies would be necessary for an appropriate dose of intravitreal injection of bevacizumab.

In conclusion, 1.25 mg/0.05 mL of a single intravitreal injection of bevacizumab significantly reduces the concentrations of VEGF in the aqueous humor of the fellow untreated eye. Thus, we need to be more careful about the fellow untreated eyes and examine patients for systemic changes.

## Author Disclosure Statement

No competing financial interests exist.

## References

1. Adamis, P., Miller, W., Bernal, T., et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. *Am. J. Ophthalmol.* 118: 445–450, 1994.
2. Aiello, P., Avery, L., Arrigg, G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic reti-

nopathy and other retinal disorders. *N. Engl. J. Med.* 331:1480–1487, 1994.

3. Avery, L., Pieramici, J., Rabena, D., et al. Intravitreal bevacizumab (Avastin®) for neovascular age-related macular degeneration. *Ophthalmology* 113:363–372, 2006.
4. Avery, L., Pearlman, J., Pieramici, J., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. *Ophthalmology* 113:1695–1705, 2006.
5. Rosenfeld, J., Fung, E., and Puliafito, A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. *Ophthalmic Surg. Lasers Imaging* 36:336–339, 2005.
6. Yoon, Y.H., Kim, J.G., Chung, H., and Lee SY. Rapid progression of subclinical age-related macular degeneration in the untreated fellow eye after intravitreal bevacizumab. *Acta Ophthalmol.* 87:685–687, 2009.
7. Sawada, O., Kawamura, H., Kakinoki, M., et al. Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab. *Graefes Arch Clin. Exp. Ophthalmol.* 246:1379–1381, 2008.
8. Meyer, C.H., Krohne, T.U., and Holz, F.G. Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans. *Acta Ophthalmol.* 2010 Feb 16. DOI: 10.1111/j.1755-3768.2009.01842 [Epub ahead of print]
9. Roth, D.B., King, A., Weiss, M., and Klein, D. Systemic adverse events after bevacizumab. *Ophthalmology* 116:1226.e1, 2009.
10. Jeganathan, V.S., and Verma, N. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration. *Curr. Opin. Ophthalmol.* 20:223–225, 2009.
11. Matsuyama, K., Ogata, N., Matsuoka, M., Wada, M., Takahashi, K., and Nishimura, T. Plasma levels of vascular endothelial growth factor and pigment epithelium derived factor before and after intravitreal injection of bevacizumab. *Br. J. Ophthalmol.* 94: 1215–1218, 2010.
12. Sawada, O., Kawamura, H., Kakinoki, M., et al. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. *Arch Ophthalmol.* 125:1363–1366, 2007.
13. Matsuyama, K., Ogata, N., Jo, N., et al. Levels of vascular endothelial growth factor and pigment epithelium derived factor in eyes before and after intravitreal injection of bevacizumab. *Jpn. J. Ophthalmol.* 53:243–248, 2009.
14. Chan, W.M., Lai, T.Y., Chan, K.P., et al. Changes in aqueous vascular endothelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. *Retina* 28:1308–1313, 2008.
15. Mordenti, J., Thomsen, K., Licko, V., et al. Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. *Toxicol. Sci.* 52:101–106, 1999.
16. Shahar, J., Avery, L., Heilweil, G., et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab. *Retina* 26:262–269, 2006.
17. Heiduschka, P., Fietz, H., Hofmeister, S., et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. *Invest Ophthalmol. Vis. Sci.* 48:2814–2823, 2007.
18. Miyake, T., Sawada, O., Kakinoki, M., Sawada, T., Kawamura, H., Ogasawara, K., and Ohji, M. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. *Invest. Ophthalmol. Vis. Sci.* 51; 2010:1606–1608.
19. Csaky, K., and Do, D.V. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. *Am. J. Ophthalmol.* 148:647–656, 2009.
20. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification. ETDRS Report Number 10. *Ophthalmology* 98:786–806, 1991.

Received: December 23, 2010
Accepted: April 30, 2011

Address correspondence to:
*Prof. Nahoko Ogata*
*Department of Ophthalmology*
*Nara Medical University*
*840 Shijo-cho, Kashihara*
*Nara 634-8522*
*Japan*

*E-mail:* ogata@naramed-u.ac.jp; ogata@takii.kmu.ac.jp

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Volume 27, Number 5, 2011
© Mary Ann Liebert, Inc.
DOI: 10.1089/jop.2011.0020

# Efficacy and Safety of Switching from Topical Latanoprost to Bimatoprost in Patients with Normal-Tension Glaucoma

Shino Sato,[1] Kazuyuki Hirooka,[1] Tetsuya Baba,[1] Masanori Mizote,[1] Takashi Fujimura,[2]
Kaori Tenkumo,[2] Hirokazu Ueda,[3] and Fumio Shiraga[1]

## Abstract

*Purpose:* The aim of this study was to evaluate the efficacy and safety of bimatoprost in Japanese patients with normal-tension glaucoma (NTG) who showed insufficient response to latanoprost.
*Methods:* A prospective, nonrandomized study was conducted in patients with NTG, with ≤20% intraocular pressure (IOP) decrease from pretreatment baseline with latanoprost monotherapy who had been switched to bimatoprost. The IOP was measured at 4, 8, and 12 weeks after the switch to bimatoprost. In 12 weeks after the switch to bimatoprost, efficacy and safety were evaluated.
*Results:* Postswitch to bimatoprost, IOP was significantly reduced at every visit. Bimatoprost produced significantly greater mean% IOP reduction rate from pretreatment than that of latanoprost at week 12 ($P<0.01$). There was a significant correlation between% IOP reduction of bimatoprost and that of latanoprost (Pearson $r^2=0.374$; $P=0.007$). No significant difference was observed in the mean scores of conjunctival hyperemia and corneal epithelial disorder between bimatoprost-treated eyes and latanoprost-treated eyes.
*Conclusions:* Significant additional IOP lowering was achieved by switching to bimatoprost in Japanese patients with NTG with insufficient response to latanoprost. Bimatoprost treatment was safe and well tolerated.

## Introduction

PROSTAGLANDIN ANALOGS have gained widespread clinical use for treatment of glaucoma because of their efficacy at lowering intraocular pressure (IOP).[1–3] Latanoprost is a prodrug of the naturally occurring prostaglandin (PG) $F_{2\alpha}$ and is endowed with a strong IOP-reducing effect.[4–6] Bimatoprost is an analog of $PGF_{2\alpha}$-1-ethanolamide (prostamide $F_{2\alpha}$). Prostamides are derived from an endocannabinoid anandamide by COX-2,[7] and have pharmacological and biochemical properties distinct from PG $F_{2\alpha}$.[7,8] Similar to $PGF_{2\alpha}$ analogs, the IOP lowering mechanism of bimatoprost is likely to be attributed to the increase in uveoscleral outflow,[9] which is associated with extracellular matrix remodeling.[10] In addition, in subjects with ocular hypertension (OH) and glaucoma, the increase of both the pressure-sensitive (trabecular) outflow and the pressure-insensitive (uveoscleral) outflow by bimatoprost could be ascribed to the changes in the trabecular meshwork or in the sclera, or both.[9,11–13] Although the pharmacological mechanisms of actions of latanoprost and bimatoprost have been thought to be similar, there is a possibility that with patients for whom 1 agent is neither fully effective nor tolerable, another agent may be useful.[14]

The Tajimi study, which is one of the largest glaucoma epidemiology studies in Japan, showed that the glaucoma prevalence rate in Japanese older than 40 years of age is 5.0%, and the rate of open-angle glaucoma is 3.9%.[15,16] The study also reported that almost 90% of the open-angle glaucoma consisted of normal-tension glaucoma (NTG). The NTG is a clinical entity characterized by glaucomatous optic nerve damage and visual field defects with an IOP in the statistically normal range. The IOP is, however, a part of the pathogenic process in NTG, and IOP lowering is effective in reducing the progression of glaucomatous damage.[17] Although latanoprost is commonly used as first-line therapy in the treatment of NTG, there are some cases that show insufficient response to latanoprost.[18]

The purpose of this study was to evaluate the efficacy and safety of bimatoprost in eyes with insufficient response to latanoprost in Japanese patients with NTG.

[1]Department of Ophthalmology, Kagawa University Faculty of Medicine, Miki, Kagawa, Japan.
[2]Department of Ophthalmology, Social Insurance Ritsurin Hospital, Takamatsu, Kagawa, Japan.
[3]Ueda Eye Clinic, Ayauta, Kagawa, Japan.

## Methods

This clinical trial was conducted at the following 3 investigational sites. December 2009 to December 2010: Department of Ophthalmology, Kagawa University Faculty of Medicine, Social Insurance Ritsurin Hospital, and Ueda Eye Clinic (Kagawa, Japan). All the aspects of the study were in compliance with the Declaration of Helsinki, and all the patients gave their consent on being sufficiently informed by an investigator.

Examinations of visual acuity, refraction, both central and peripheral fields, slit-lamp examination, and gonioscopy were performed on all the patients. The eligibility criteria were age ≥20 years; bilateral or unilateral NTG: glaucomatous optic disc abnormalities and corresponding glaucomatous visual field defects, normal open angle, and IOP (measured using Goldmann applanation tonometer) of 21 mmHg or lower without medication; ≤20% IOP decrease from pretreatment baseline at least 12 weeks of treatment with latanoprost 0.005% (Xalatan®; Pfizer, New York, NY) monotherapy. Exclusion criteria were the subjects being with active ocular diseases in either eye except glaucoma; with retinal disease that has a potential risk of progression; with experience of ocular surgery or lazer treatment; with regimen for systemic or local administration of steroid during this study; with corneal disease in either eye that poses a problem for veracious IOP measurement.

A total of 18 patients who fit the study criteria were enrolled in this study. The study consisted of 4 scheduled visits over 12 weeks (day 0 and weeks 4, 8, and 12). At day 0 (preswitch), eligible patients who had used latanoprost 0.005% were switched to bimatoprost 0.03% (Lumigan®; Allergan, Inc., Irvine, CA) treatment. The administration time of bimatoprost had been set to just around the same time before administration of latanoprost.

Measurements of IOP, best-correlated visual acuity, and biomicroscopic examinations were conducted at each visit. The IOP was measured at the same time period during the administration of latanoprost with Goldmann applanation tonometer by using the same procedure at all centers. The outcome due to primary efficacy was the main change in IOP at week 12 from preswitch.

Biomicroscopy was performed by using a slit-lamp examination without pupil dilation. The examination included an assessment of the lid/lashes, conjunctiva, anterior chamber, cornea, iris, and lens. Conjunctival hyperemia was assessed by a single observer by using a 5-point hyperemia grading scale using 5 different photographs for hyperemia matching: 0 = none, 0.5 = trace, 1 = mild, 2 = moderate, and 3 = severe. Corneal epithelial disorders were recorded by using an A (area) D (density) grading scale by a slit-lamp examination.[19]

The study outcome for efficacy was based on the conditions of the patients' eyes with the higher IOP at the eligibility visit. If IOP was same in both eyes, we analyzed the right eye. Descriptive statistics for mean IOP, mean IOP change, and% IOP change from pretreatment were calculated. Statistical significance was assessed by using paired $t$ test. The degrees of conjunctival hyperemia and corneal epithelial disorder were analyzed by using an averaged score of both eyes' values. Evaluation of the degrees of conjunctival hyperemia and corneal epithelial disorder was analyzed by using a Wilcoxon signed-rank test. The correlation mean% IOP change from pretreatment between eyes treated with latanoprost and eyes treated with bimatoprost was analyzed by using a Pearson's correlation coefficient test. All the statistical analyses were performed by using SPSS for Windows, Version 11.5 (SPSS, Inc., Chicago, IL). A $P$ value of 0.05 or less was considered statistically significant. Data are presented as mean ± standard deviation.




FIG. 1. Reduction in mean IOP after a switch to bimatoprost. Data express the mean ± SD. $^{*}P < 0.05$ versus pretreatment (paired $t$ test). $^{\#}P < 0.05$ versus preswitch (paired $t$ test). IOP, intraocular pressure; SD, standard deviation.

## Results

There were 4 men and 14 women (mean age, 68.2 ± 15.3 years), who had the mean refractive error of −2.3 ± 4.9 diopters. All subjects completed the study. No significant changes in visual acuity were detected throughout follow-up (data not shown).

The IOP data were as follows: pretreatment = 17.3 ± 1.6 mm Hg; preswitch = 16.0 ± 1.3 mm Hg; 12 weeks = 14.1 ± 1.7 mm Hg. At week 12, IOP was significantly lower than both the pretreatment IOP ($P < 0.01$) and the preswitch IOP ($P < 0.01$) (Fig. 1). Although the mean% IOP reduction from pretreatment to preswitch (latanoprost) was −7.5% ± 5.6%, the mean% IOP reduction from pretreatment to 12 weeks (bimatoprost) was −18.7% ± 8.9% (Fig. 2). At week 12, 7 patients showed ≥20% IOP decrease, and 2 patients showed ≥30% IOP decrease from pretreatment (Fig. 3). There was a




FIG. 2. Mean% IOP reduction from pretreatment to preswitch (Latanoprost) and at week 4, 8, and 12 (Bimatoprost). The mean% IOP reduction rate of bimatoprost was significantly greater than that of latanoprost ($^{*}P < 0.01$, paired $t$ test). Data express the mean ± SD.




FIG. 3. Correlation between% IOP reduction rate of bimatoprost and latanoprost. % IOP reduction rate of bimatoprost was significantly correlated with that of latanoprost. (Pearson correlation coefficient $R^2 = 0.374$; $P = 0.007$).

significant correlation between% IOP reduction of bimatoprost and that of latanoprost (Pearson correlation coefficient $r^2 = 0.374$; $P < 0.01$) (Fig. 3).

The mean hyperemia scores at preswitch and week 12 were 0.31±0.35 and 0.56±0.54 ($P = 0.27$), respectively (Table 1). The mean corneal epithelial disorder scores at preswitch and week 12 were 0.67±0.97 and 0.67±0.97 ($P > 0.99$), respectively (Table 1).

## Discussion

The incidence rate of latanoprost nonresponders is reported at 28.1% and was highest in patients with NTG in Japan.[18] The reduction of IOP in patients with lower baseline IOP may be more difficult.[20] Several studies revealed that the IOP-lowering effect of bimatoprost was even equal to or higher than that of latanoprost.[2,11–14]

Bimatoprost was difficult to be converted to its free acid form in human eyes, and free acid was slightly detected at the site of action in the eye.[8,21,22] In contrast, latanoprost is a prodrug that needs de-esterification to yield a pharmacologically active free fatty acid. Due to this, the pharmacological effect of bimatoprost is difficult to be attenuated because of its metabolism compared with latanoprost. Gandolfi and Cimino[14] previously reported that most of the subjects with glaucoma or OH who showed no significant IOP response to latanoprost were successfully treated with bimatoprost. They speculated that the lack of response to latanoprost was associated with poor de-esterification of the prodrug to the pharmacologically active free fatty acid. In early studies, the additional IOP-lowering effect of bimotoprost was seen in patients who responded poorly to latanoprost, thus suggesting a superior IOP-lowering effect of bimatoprost, compared with latanoprost.[14,23] Mean IOP before the switch to bimatoprost, however, was approximately 23 mm Hg in their study.[14,23] Our study suggests that the decrease of IOP also occurred with switching to bimatoprost in Japanese patients who are insufficient responders to latanoprost even though pretreatment IOP is low.

In this study, we showed that the mean IOP reduction rate of bimatoprost was significantly correlated with the mean IOP reduction rate of latanoprost. Bimatoprost showed a trend to enhance the potency of latanoprost. Prostaglandin $F_{2\alpha}$ (FP) prostanoid receptors are G-protein coupled receptors that mediate the actions of PG $F_{2\alpha}$, which is confirmed to be an alternative splice variant of the human FP (altFP) prostanoid receptor gene.[24] Since bimatoprost interacts not with PG FP receptor but with prostamide receptor, bimatoprost is likely to have a pharmacologically inherent receptor.[7,8] It has been reported that bimatoprost may interact with the FP-altFP receptor heterodimer to induce alterations in second-messenger signaling.[25] FP-altFP complexes may represent the underlying basis of bimatoprost pharmacology.[25] Since prostamide and FP receptors may be encoded by the same gene, the lowering effects on IOP of bimatoprost might correlate with those of latanoprost.

Conjunctival hyperemia was the most commonly reported side effect of bimatoprost and the most frequently observed biomicroscopic finding in several studies.[2,3,14] Conjunctival hyperemia occurs more frequently with bimatoprost than with latanoprost.[26] There were, however, no significant differences in the mean score of conjunctival hyperemia between bimatoprost-treated eyes and latanoprost-treated eyes in this study. The switch from latanoprost to bimatoprost in the glaucoma therapy was associated with less conjunctival hyperemia than that measured in patients in whom bimatoprost was used as first-line therapy.[27] One of the limitations of this study is that there was no control group. There is the possibility that some patients who had conjunctival hyperemia caused by latanoprost may continue after withdrawal. Ocular surface hyperemia occurs by endothelial-derived nitric oxide-mediated vasodilatation and is not associated with intraocular inflammation.[28] Even though there is a trend toward exacerbation during the switching phase, no patients withdrew from the treatment. In addition, the deepening of eyelid sulcus due to bimatoprost has been reported.[29] Although 1 patient complained of the deepening of eyelid sulcus, the patient continued the treatment.

Low ocular perfusion pressure is an established risk factor in glaucoma.[30] Quaranta et al.[31] recently reported that in previously untreated patients with NTG, both latanoprost and bimatoprost reduced the IOP from untreated baseline, to a similar extent, over a 24-h curve. Latanoprost was associated with slightly improved ocular diastolic perfusion pressure over 24-h but similar absolute perfusion levels to those of bimatoprost.[31]

In conclusion, bimatoprost provided a significant reduction in IOP for at least 12 weeks for Japanese patients with NTG who showed insufficient response to latanoprost.

TABLE 1. MEAN CONJUNCTIVAL HYPEREMIA AND AREA DENSITY GRADING SCALE SCORES

| | *Mean conjunctival hyperemia* | *Mean area density grading scale score* |
|---|---|---|
| Preswitch | 0.31±0.35 | 0.67±0.97 |
| At 4 weeks | 0.47±0.41 ($P = 0.60$) | 0.94±1.20 ($P = 0.78$) |
| At 8 weeks | 0.50±0.54 ($P = 0.46$) | 0.78±1.00 ($P = 0.98$) |
| At 12 weeks | 0.56±0.54 ($P = 0.27$) | 0.67±0.97 ($P > 0.99$) |

## Author Disclosure Statement

No competing financial interests exist.

## References

1. Whitcup, S.M., Cantor, L.B., VanDenburgh, A.M., and Chen, K. A randomized, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of

glaucoma and ocular hypertension. *Br. J. Ophthalmol.* 87:57–62, 2003.
2. Noecker, R.S., Dirks, M.S., Choplin, N.T., et al. Bimatoprost/Latanoprost Study Groupe. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. *Am. J. Ophthalmol.* 135:55–63, 2003.
3. Parrish, R.K., Palmberg, P., and Sheu, W.P; XLT Study Group. A comparison of latanoprost, bimatoprost, and tavoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. *Am. J. Ophthalmol.* 135:688–703, 2003.
4. Alm, A., and Stjernschantz, J. Effect of intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. *Ophthalmology* 102:1743–1752, 1995.
5. Camras, C.B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. *Ophthalmology* 103:138–147, 1996.
6. Watson, P., and Stjernschantz, J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open angle glaucoma and ocular hypertension. The Latanoprost Study Group. *Ophthalmology* 103:126–137, 1996.
7. Woodward, D.F., Liang, Y., and Krauss, A.H. Prostamides (prostaglandin-ethanolamides) and their pharmacology. *Br. J. Pharmacol.* 153:410–419, 2008.
8. Woodward, D.F., Krauss, A.H.P., Chen, J., et al. The pharmacology of bimatoprost (Lumigan). *Surv. Ophthalmol.* 45(Suppl 4):S337–S345, 2001.
9. Brubaker, R.F., Schoff, E.O., Nau, C.B., et al. Effect of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. *Am. J. Ophthalmol.* 131:19–24, 2001.
10. Richter, M., Krauss, A.H., Woodward, D.F., and Lütjen-Drecoll, E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. *Invest. Ophthalmol. Vis. Sci.* 44:4419–4426, 2003.
11. Lim, K.S., Nau, C.B., O'Byrne, M.M., et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. *Ophthalmology* 115:790–795, 2008.
12. Christiansen, G.A., Nau, C.B., McLaren, J.W., and Johnson, D.H. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. *Ophthalmology* 111:1658–1662, 2004.
13. Wan, Z., Woodward, D.F., Cornell, C.L., et al. Bimatoprost, prostamide activity, and conventional drainage. *Invest. Ophthalmol. Vis. Sci.* 48:4107–4115, 2007.
14. Gandolfi, S.A., and Cimino, L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. *Ophthalmology* 110;609–614, 2003.
15. Iwase, A., Suzuki, Y., Araie, M., et al.; Tajimi Study Group, Japan Glaucoma Society. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. *Ophthalmology* 111:1641–1648, 2004.
16. Yamamoto, T., Iwase, A., Araie, M., et al.; Tajimi Study Group, Japan Glaucoma Society. The Tajimi Study report 2: prevalence of primary angle closure and secondary glaucoma in a Japanese population. *Ophthalmology* 112:1661–1669, 2005.
17. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressure. *Am. J. Ophthalmol.* 126:487–497, 1998.
18. Ikeda, Y., Mori, K., Ishibashi, T., et al. Latanoprost nonresponders with open-angle glaucoma in Japanese population. *Jpn. J. Ophthalmol.* 50:153–157, 2006.
19. Miyata, K., Amano, S., Sawa, M., and Nishida, T. A novel grading method for superficial punctate keratopathy magnitude and its correlation with corneal epithelial permeability. *Arch. Ophthalmol.* 121:1537–1539, 2003.
20. Rulo, A.H., Greve, E.L., Geijssen, H.C., and Hoyng PF. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. *Ophthalmology* 103:1276–1282, 1996.
21. Cantor, L.B., Hoop, J., Wudunn, D., et al. Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract. *Br. J. Ophthalmol.* 91:629–632, 2007.
22. Woodward, D.F., Krauss, A.H., Chen, J., et al. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). *J. Pharmacol. Exp. Ther.* 305:772–785, 2003.
23. Sonty, S., Donthamsetti, V., Vangipuram, G., and Ahmad, A. Long-term IOP lowering with bimatoprost in open-angle glaucoma patients poorly responsive to latanoprost. *J. Ocul. Pharmacol. Ther.* 24:517–520, 2008.
24. Vielhauer, G.A., Fujino, H., and Regan, J.W. Cloning and localization of hFP(S): a six-transmembrane mRNA splice variant of the human FP prostanoid receptor. *Arch. Biochem. Biophys.* 15:175–185, 2004.
25. Liang, Y., Woodward, D.F., Guzman, V.M., et al. Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes. *Br. J. Pharmacol.* 154:1079–1093, 2008.
26. Honrubia, F., García-Sánchez, J., Polo, V., Martínez de la Cass, J.M., and Soto, J. Conjunctival hyperemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomized clinical trials. *Br. J. Ophthalmol.* 93:316–321, 2009.
27. Kurtz, S., and Mann, O. Incidence of hyperemia associated with bimatoprost treatment in naïve subjects and in subjects previously treated with latanoprost. *Eur. J. Ophthalmol.* 19: 400–403, 2009.
28. Chen, J., Dinh, T., Woodward, D.F., et al. Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy. *Cardiovasc. Drug Rev.* 23:231–246, 2005.
29. Yam, J.C., Yuen, N.S., and Chan, C.W. Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. *J. Ocul. Pharmacol. Ther.* 25:471–472, 2009.
30. Caprioli, J., and Coleman, A.L. Blood Flow in Glaucoma Discussion. Blood pressure, perfusion pressure, and glaucoma. *Am. J. Ophthalmol.* 149:704–712, 2010.
31. Quaranta, L., Pizzolante, T., Riva, I., Haidich, A.B., Konstas, A.G., and Stewart, W.C. Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma. *Br. J. Ophthalmol.* 92:1227–1231, 2008.

Received: February 7, 2011
Accepted: June 27, 2011

Address correspondence to:
*Dr. Kazuyuki Hirooka*
*Department of Ophthalmology*
*Kagawa University Faculty of Medicine*
*1750-1 Ikenobe*
*Miki, Kagawa 761-0793*
*Japan*

*E-mail:* kazuyk@med.kagawa-u.ac.jp

*Current Eye Research*, 36(12), 1153–1163, 2011
Copyright © 2011 Informa Healthcare USA, Inc.
ISSN: 0271-3683 print/ 1460-2202 online
DOI: 10.3109/02713683.2011.606592

informa
healthcare

RESEARCH ARTICLE

# Increased Expression of Tight Junctions in ARPE-19 Cells Under Endoplasmic Reticulum Stress

Tadanobu Yoshikawa[1], Nahoko Ogata[2], Hiroshi Izuta[3], Masamitsu Shimazawa[3], Hideaki Hara[3], and Kanji Takahashi[4]

*[1]Department of Ophthalmology, Kansai Medical University, Takii Hospital, Osaka, Japan, [2]Department of Ophthalmology, Nara Medical University, Nara, Japan, [3]Department of Biofunctional Evaluation Molecular Pharmacology, Gifu Pharmaceutical University, Gifu, Japan, and [4]Department of Ophthalmology, Kansai Medical University, Hirakata Hospital, Osaka, Japan*

## ABSTRACT

*Purpose*: To investigate the effects of endoplasmic reticulum (ER) stress on the tight junctions of the retinal pigment epithelial (RPE) cells *in vitro*.

*Materials and Methods*: ER stress was induced in cultured ARPE-19 cells, a human RPE cell line, by exposure to tunicamycin (TM) or to thapsigargin (TG). After 6, 12, 24 and 48 hours of exposure, the expressions of GRP78/Bip (Bip), C/EBP-homologous protein (CHOP), vascular endothelial growth factor (VEGF), zonula occludens (ZO)-1, occludin and claudin-1 were determined by real-time RT-PCR. Immunoblot analysis and/or immunohistochemistry for proteins of tight junctions and ER stress markers, viz., Bip, activating transcription factor (ATF) 6, CHOP, and caspase-4, were performed at 48 hours after the exposure. Enzyme-linked immunosorbent assay was used to determine the concentration of VEGF165. Transepithelial electrical resistance (TER) of the ARPE-19 cells was determined to measure the permeability.

*Results*: The expressions of the mRNAs and/or proteins of Bip, CHOP, ATF6 and caspase-4 were significantly increased in ARPE-19 cells under ER stress induced by TM and TG. The mRNAs of VEGF were also increased by both TM and TG. However, the concentration of VEGF165 was not significantly increased after 48 hours exposure to TM and TG compared to that of the control in the apical chamber medium. The proteins and mRNAs of occludin and claudin-1 were significantly increased by TM and TG, and that of ZO-1 was significantly increased by TG. Immunohistochemistry showed that the staining of ZO-1, occludin and claudin-1 under ER stress was stronger than that of the control. A significant increase of TER was observed after exposure to TM and TG.

*Conclusions*: The increased expressions of tight junction molecules by TM– or TG-exposed ARPE-19 cells indicate that ER stress can alter the function of RPE cells and may be involved in the pathogenesis of age-related macular degeneration.

**Keywords:** Endoplasmic reticulum (ER) stress, Tight junction, Age-related macular degeneration (AMD), Retinal pigment epithelium (RPE), Transepithelial electrical resistance (TER)

Copyright © Informa Healthcare. Not for Sale. Unauthorized use prohibited.

For personal use only.

## INTRODUCTION

The endoplasmic reticulum (ER) is an important intracellular organelle responsible for the biosynthesis and folding of proteins.[1] It is also an early signal transduction site that responds to different cellular stressors, such as hypoxia, oxidative stress, glucose starvation and upset of the calcium homeostasis.[2] ER stress results from an accumulation of unfolded or misfolded proteins in the ER which leads to the activation of ER-localized transmembrane proteins, and activating transcription factor 6 (ATF6). ATF6 can then initiate the unfolded protein response (UPR).[3] While transient and low grade ER stress can be overcome by the UPR, persistent and severe ER stress results in the expression of inflammatory genes and apoptosis.[4–6]

ER stress has been linked to the pathogenesis of several diseases, including vascular and

Received 31 January 2011; accepted 04 July 2011

Correspondence: Nahoko Ogata, MD, PhD, Professor and Chairman, Department of Ophthalmology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634–8522, Japan. Tel: +81–744-29–8884 (ext.3432). Fax: +81–744-23–8032. E-mail: ogata@takii.kmu.ac.jp



RIGHTSLINK

neurodegenerative diseases such as stroke,[7] diabetes mellitus,[8] Alzheimer disease[9] and Parkinson disease.[10] In the eye, recent studies have shown that ER stress is associated with diabetic retinopathy and age-related macular degeneration (AMD).[11–13] However, little is known about the role of ER stress in retinal damage.

The retinal pigment epithelial (RPE) cell is a highly specialized epithelium that has multifunctional and essential roles in the vertebrate eye.[14] The RPE forms the outer blood–retinal barrier (BRB), and thus controls the flow of solutes and fluid from the choroidal vasculature into the outer retina.[15] Therefore, RPE plays an important role in the pathogenesis of retinal diseases.

The strict control of fluid and solutes across the BRB is achieved through well developed tight junctions. Over 40 proteins have been found to be associated with tight junctions.[16] Zonula occludens (ZO)-1, claudins and occludin are the most studied of these proteins, especially how they are related to the BRB. However, to the best of our knowledge the effect of ER stress on the barrier functions of the RPE has still not been reported. Thus, the purpose of this study was to determine how ER stress affects the expression of the tight junction molecules in the RPE. To do this, we exposed cultured ARPE-19 cells, a human RPE cell line, with two ER stress inducers, tunicamycin (TM) and thapsigargin (TG). TM, a glucosamine-containing nucleoside antibiotic, is an inhibitor of N-linked glycosylation.[17] It inhibits dolichol pyrophosphate-mediated glycosylation of asparaginyl and residues of glycoproteins,[18] which causes an accumulation of unfolded proteins in the ER and induces ER stress.[19] TG, a highly lipophilic sesquiterpene lactone, is the most widely used inhibitor of the sarcoplasmic reticulum calcium-ATPase, which pumps $Ca^{2+}$ into the ER of mammalian cells. The TG-mediated inhibition of the $Ca^{2+}$ATPases in the ER elevates the intracellular Ca which leads to an accumulation of unfolded protein.[20,21] This then induces ER stress.

We investigated how ER stress affected the expression of ZO-1, claudin-1 and occludin and also the expression of vascular endothelial growth factor (VEGF). We also tested whether ER stress affected the barrier function of ARPE-19 cells. We shall show that ER stress altered the tight junctions and increased the barrier function of RPE.

Curr Eye Res Downloaded from informahealthcare.com by Maruzen Co Ltd on 05/01/12
For personal use only.

## MATERIALS AND METHODS

### RPE Cell Cultures

ARPE-19 cells were purchased from the American type culture collection (ATCC, Manassas, VA) and were cultured in Dulbecco modified Eagle medium/F-12 human amniotic membrane nutrient mixture (DMEM/F-12; Gibco, Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (Hyclone, Thermo Scientific, Rockford, IL). The cultures were grown in a humidified incubator at 37°C in an atmosphere of 5% $CO_2$.

### Preparation of Reagents

TG (Sigma-Aldrich, St. Louis, MO) was dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich) at a concentration of 3 mM to produce stock solutions. The stock solutions were diluted with DMEM/F-12 medium to obtain 1 μM TG-containing culture medium. To evaluate the effect of DMSO, medium containing only DMSO (1:5000 of total volume) was also used for each study. For TM (Sigma-Aldrich), 1 μg/ml was used for each study. The concentrations of TG and TM used to treat ARPE-19 cells were based on the results of earlier studies.[12,22]

### cDNA Preparation and Real-Time PCR

Real-time PCR was performed after 0, 6, 12, 24 and 48 hours of exposure to TM or TG to detect the mRNA expression of ER stress markers, viz., GRP78/Bip (Bip), C/EBP-homologous protein (CHOP) and VEGF. In addition, the mRNAs of tight junctions, ZO-1, occludin and claudin-1 in ARPE-19 cells, were also determined at the same times.

After exposure to each agent, cDNAs were prepared from the ARPE-19 cells with Fast SYBR® Green Cells-to-CT™ Kit (Ambion, Austin, TX) according to the manufacture's protocol. Briefly, ARPE-19 cells were lysed with DNase I (1:100), reaction was placed in a stop solution, then enrolled to reverse transcription (RT) using 10 μl of cell lysate in a RT Master Mix at 37°C for 60 min and 95°C for 5 min.

Real-time RT-PCR was performed using 4 μl of the prepared cDNA samples with PCR Master Mix with SYBR green (Fast SYBR® Green Cells-to-CT™ Kit, Ambion) and PCR primers on a thermal cycler (Opitcon2, MJ Research, California, USA) according to the manufacturer's instructions. After a denaturation step at 95°C for 20 seconds, amplification by two steps of 40 cycles for 3 seconds at 95°C and 30 seconds at 60°C followed. The concentrations of the PCR products were measured by fluorescence associated with the binding of the double-stranded DNA to the SYBR green dye in the reaction mixture. All experiments were repeated independently four times in triplicate. The sequences of the primers used are listed in Table 1. Quantification of each PCR product was expressed relative to GAPDH.

### Western Blot Analysis

Western blot analysis was performed to detect the ER stress markers, viz., Bip, ATF6, CHOP, and caspase-4, and the tight junction proteins, viz., ZO-1, occludin and claudin-1. After exposure to TM or TG for 48 hours, cells were lysed in RIPA buffer (product No. R0278, Sigma-Aldrich) containing protease inhibitors (cocktails

RIGHTSLINK

TABLE 1 Primer sequences.

| Genes | Oligo names | Sequences |
|---|---|---|
| GAPDH | Forward | GCACCGTCAAGGCTGAGAAC |
| | Reverse | TGGTGAAGACGCCAGTGGA |
| Bip/GRP78 | Forward | GGCGTGGTAGTGCAAGCTGA |
| | Reverse | CCTATCCTTGGGCAGTATTGGATTC |
| CHOP | Forward | GCGCATGAAGGAGAAAGAAC |
| | Reverse | TCACAATTCGGTCAATCAGA |
| ZO-1 | Forward | GACCAATAGCTGATGTTGCCAGAG |
| | Reverse | TGCAGGCGAATAATGCCAGA |
| Occludin | Forward | AAGAGTTGACAGTCCCATGGCATAC |
| | Reverse | ATCCACAGGCGAAGTTAATGGAAG |
| Claudin-1 | Forward | CTGACATGTTTGTGCTCTGTTCCA |
| | Reverse | GCAGCCAAATGCCTTGCTC |
| VEGFA | Forward | TCACAGGTACAGGGATGAGGACAC |
| | Reverse | TCCTGGGCAACTCAGAAGCA |

of product No. P2850 and 5726, Sigma-Aldrich). The protein concentration was determined by the bicinchoninic acid protein assay (Pierce Biotechnology Inc., Rockford, IL). Ten micrograms of protein were solubilized in by SDS–PAGE sample buffer (Nacalai tesque, Osaka, Japan), separated on SDS-PAGE, then transferred to polyvinylidene difluoride membrane (Bio-Rad Laboratories, Hercules, CA). After blocking, the membrane was incubated with specific antibodies, viz., mouse anti-Bip/GRP78 antibody (BD Biosciences, CA, USA, 1:1000), mouse anti-GADD153/CHOP antibody (Santa cruz biotechnology, CA, USA, 1:400), mouse anti-caspase-4 antibody (MBL, Nagoya, Japan, 1:1000), rabbit anti- ATF6 antibody (Abcam, Cambridge, MA, USA, 1:2000), rabbit anti- ZO-1 antibody (Invitrogen, Camarillo, CA, 1:1000), rabbit anti-occludin antibody (Invitrogen, 1:1000), and rabbit anti-claudin-1 antibody (Invitrogen, 1:1000) overnight at 4°C. After washing, the secondary antibodies, viz., goat anti-rabbit HRP-conjugated antibody (Santa cruz biotechnology, 1:2000) or goat anti-mouse HRP-conjugated antibody (Santa cruz biotechnology, 1:2000) were applied for 15 min at room temperature.

The specific protein bands were made visible with an enhanced chemiluminescence detection system (super signal west femto maximum sensitivity substrate, Thermo Scientific) and were measured using a digital image analyzer (LAS4000mini, FujiFilm, Tokyo, Japan). The same membranes were blotted with HRP-conjugated goat anti-actin polyclonal IgG antibody (Santa cruz biotechnology, 1:10,000) to normalize the protein levels. All experiments were repeated independently four times in triplicate.

## Immunohistochemistry

Immunohistochemistry was performed in cells grown on a circular culture cover glass (13 mm of diameter) coated with poly-L-lysin in 24-well plates (Matsunami Glass Ind., Ltd., Osaka, Japan). ER stress was induced by exposure of the cells to TM or TG for 48 hours. The cells were then washed with phosphate buffered saline (PBS) and fixed with 4% paraformaldehyde for 10 min, washed with 50 mM glycine in PBS three times, permeabilized by 0.1% TritonX-100 in PBS for 10 min, washed with 50 mM glycine in PBS again and blocked with 3% bovine serum albumin (BSA) in PBS for 30 min at room temperature.

The cover slips were exposed to rabbit anti-ZO-1, occludin, or claudin-1 antibodies (Invitrogen, 1:250) for 30 min at 37°C. After washing with 0.1% BSA in PBS, cells were further incubated with goat anti-rabbit IgG Alexa Fluor 488 (Molecular Probes, Invitrogen) for 30 min at 37°C, then washed with 0.1% BSA in PBS. Immunohistochemistry was performed in four independent experiments. The cells were mounted on microscope slides with Aqua-Poly/Mount (Polysciences, Inc, Warrington, PA, USA). Photographs were taken with a confocal laser scanning fluorescence microscope (BX51, Olympus, Tokyo, Japan).

## Measurement of Transepithelial Electrical Resistance (TER)

ARPE-19 cells were grown on microporous filter membranes (0.4 μm pore size and 6.5 mm in diameter; Transwell, Costar, Corning Inc., Corning, NY) of apical chambers. The membrane was supported in 24-well culture plates. The cultures were started at a concentration of $3 \times 10^4$ cells/well and grown to confluence with exposure to TM or TG for 48 hours. The TER was measured with an epithelial voltmeter (EVOM2, World Precision Instruments, Sarasota, FL, USA) with electrodes (STX2, World Precision Instruments) according to the manufacturer's instructions.

The TER values were determined by subtracting the resistance of the filter alone (background) from the values obtained with the filters and the RPE cells. The resistance/unit area was equal to the resistance (ohm) × effective membrane area ($cm^2$). Measurements were repeated at least twice for each well in four independent experiments, and each experiment was repeated for at least five different wells.

## Enzyme-Linked Immunosorbent Assay (ELISA)

ARPE-19 cells were seeded in 24-well culture plates in the same way as that used to measure the TER. The supernatants of the apical and basolateral chambers were collected and stored at −20°C. ELISA was performed using a human VEGF ELISA kit (Quantikine; R&D Systems, Mineapolis, MN, USA), according to the manufacturer's instructions. ELISA was performed in triplicate in three independent experiments.

© 2011 Informa Healthcare USA, Inc.

For personal use only.

RIGHTSLINK

## Statistical Analyses

Data were statistically analyzed by a one-way ANOVA, and results are expressed as means ± standard error of the means (SEMs). A $P$ value < 0.05 was accepted as significant.

## RESULTS

Induction of ER stress markers, Bip, ATF6, CHOP, and caspase-4, after exposure to TM or TG

Bip is an established ER-resident chaperon, which binds to the ER stress sensors, but binds more stably to misfolded or unfolded proteins.[3] Thus, an up-regulation of Bip is one of the most commonly used markers of ER stress. CHOP, a commonly used marker of ER stress, is a member of the CCAAT/enhancer-binding protein family that is induced by ER stress. It is a sign of an activation of the UPR and participates in ER-mediated apoptosis.[23]

Therefore, we first investigated the expressions of Bip and CHOP in the ARPE-19 cells exposed to TM or TG. The expressions of Bip and CHOP mRNA were significantly up-regulated by TM exposure after 6, 12, 24, and 48 hours (Bip, 4.1-fold, 4.5-fold, 4.1-fold, and 5.1-fold; $P<0.001$, $P<0.001$, $P<0.001$, and $P<0.001$, respectively: CHOP, 44.2-fold, 47.2-fold, 52.1-fold, and 88.4-fold; $P<0.001$, $P<0.001$, $P<0.001$, and $P<0.001$, respectively) compared to that of the initial levels (Figure 1A).

The expressions of the mRNAs of Bip and CHOP were also significantly up-regulated by TG exposure after 6, 12, 24, and 48 hours (Bip, 5.4-fold, 7.2-fold, 6.7-fold, and 9.5-fold; $P<0.001$, $P<0.001$, $P<0.001$, and $P<0.001$, respectively; CHOP, 44.2-fold, 82.6-fold, 84.4-fold, and 83.0-fold; $P<0.001$, $P<0.001$, $P<0.001$, and $P<0.001$, respectively) compared to that of the initial levels (Figure 1B). These results indicate that ER stress was significantly up-regulated by TM and TG.

The results of Western blot analyses are shown in Figure 1C. The expressions of Bip, ATF6, CHOP, and caspase-4 proteins were increased by after exposure to TM and TG compared to that of the controls (Figure 1C). The level of Bip was increased to 2.0-fold by TM ($P<0.05$) and to 2.3-fold by TG ($P<0.01$, Figure 1D). ATF6 was increased to 3.6-fold by TM ($P<0.01$) and to 2.2-fold by TG ($P<0.05$, Figure 1D), CHOP was increased to 40.1-fold by TM ($P<0.001$) and to 46.8-fold by TG ($P<0.05$, Figure 1D), and cleaved caspase-4 was increased to 6.9-fold by TM ($P<0.05$) and to 14.7-fold by TG ($P<0.01$, Figure 1D).

## VEGF Induction Under ER Stress-Induced by TM or TG

After 6, 12, 24, and 48 hours exposure to TM or TG, the expression of the mRNA of VEGF was up-regulated in time dependent way. It was significantly increased at 24 and 48 hours (TM, 2.1-fold at 24 hours, 3.8-fold at 48 hours; $P<0.001$, $P<0.001$, respectively; TG, 4.2-fold at 24 hours, 4.6-fold at 48 hours; $P<0.001$, $P<0.001$, respectively, Figure 2A and 2B).

The results of ELISA are shown in Figure 2C and 2D. In culture medium of the apical chamber, the concentration of VEGF165 was significantly increased after 24 hours exposure to TM and TG compared to that of the control (control, 327 pg/ml; TM, 904 pg/ml, $P<0.01$; TG 1100 pg/ml, $P<0.001$, respectively, Figure 2C) but the increase was not significant after 48 hours (control, 1541 pg/ml; TM 1897 pg/ml; TG 1886 pg/ml, respectively, Figure 2C). In culture medium of basolateral chamber, the concentration of VEGF165 was significantly increased after 24 and 48 hours exposure to TG but the increase was not significant after 24 hours exposure to TM (control, 55 pg/ml at 24 hours; TM, 61 pg/ml at 24 hours; TG 199 pg/ml at 24 hours, $P<0.05$; Control 285 pg/ml at 48 hours; TM 839 pg/ml at 48 hours, $P<0.001$; TG 1173 pg/ml at 48 hours, $P<0.001$, respectively, Figure 2D).

## Induction of Tight Junction Components Under ER Stress Induced by TM or TG

The expression of the mRNA of ZO-1 was increased under ER stress induced by TM, but the increase was not significant (Figure 3A). However, the expressions of the mRNA of occludin and claudin-1 were significantly up-regulated by TM at 6, 12, 24, and 48 hours (occludin, 2.1-fold, 3.5-fold, 4.7-fold, and 5.9-fold; $P<0.01$, $P<0.001$, $P<0.001$, and $P<0.001$, respectively; claudin-1, 3.1-fold, 3.2-fold, 3.9-fold, and 3.8-fold; $P<0.001$, $P<0.001$, $P<0.001$, and $P<0.001$, respectively) compared to that of the initial levels (Figure 3A).

The ER stress-induced by TG increased the mRNA expression of ZO-1 and it was significantly up-regulated after 24 and 48 hours (2.6-fold, 3.1-fold, $P<0.01$, $P<0.001$, respectively; Figure 3B). The mRNA expressions of occludin and claudin-1 were also up-regulated by TG exposure, and they were significantly up-regulated after 12, 24 and 48 hours compared to that of the initial levels (occludin, 4.0-fold, 8.8-fold, 8.4-fold; $P<0.01$, $P<0.001$, $P<0.001$, respectively; claudin-1, 4.1-fold, 6.8-fold, 7.4-fold; $P<0.05$, $P<0.001$, $P<0.001$, respectively; Figure 3B).

The results of Western blot analyses are shown in Figure 3C and 3D. The expression of the protein of ZO-1 under ER stress was significantly increased by TG (2.8-fold, $P<0.05$) but the increase was not significant after TM (1.7-fold, $P>0.05$, Figure 3C and 3D). The protein levels of occludin and claudin-1under ER stress were significantly increased by TM and TG compared to that of the control (Figure 3C). The level of occludin was increased to 2.8-fold by TM ($P<0.05$) and to 2.7-fold by TG ($P<0.05$, Figure 3C and 3D), and claudin-1 was

Curr Eye Res Downloaded from informahealthcare.com by Maruzen Co Ltd on 05/01/12
For personal use only.

RIGHTS LINK

For personal use only.




FIGURE 1 Induction of ER stress markers, Bip, ATF6, CHOP and caspase-4. (A) Expressions of Bip mRNA and CHOP mRNA are significantly up-regulated 6–48 hours after the TM exposure compared to that of the initial levels. (B) Expressions of Bip and CHOP mRNA are significantly up-regulated 6–48 hours after the TG exposure compared to that of the initial levels. (C) Results of Western blot and (D) densitometric analysis of Western blot. The levels of Bip, ATF6, CHOP, and caspase-4 proteins are increased by TM and TG. Data are presented as the means ± SEMs. ***$P < 0.001$.

© 2011 Informa Healthcare USA, Inc.

RIGHTSLINK




FIGURE 2 VEGF induction under ER stress-induced by TM or TG. (A) (B) After 6, 12, 24 and 48 hours TM (A) and TG (B) exposure, the expression of VEGF mRNA is up-regulated in a time dependent way, and it is significantly increased at 24–48 hours. (C) In apical chamber medium, the concentration of VEGF165 was significantly increased after 24 hours but the increase was not significant after 48 hours. (D) In the basolateral chamber medium, the concentration of VEGF165 was significantly increased after 48 hours. Data are presented as the means ± SEMs. *= $P < 0.05$, **= $P < 0.01$, ***= $P < 0.001$.

Curr Eye Res Downloaded from informahealthcare.com by Maruzen Co Ltd on 05/01/12
For personal use only.

increased to 13.6-fold by TM ($P<0.05$) and to 10.9-fold by TG ($P<0.05$, Figure 3C and 3D).

## Immunohistochemistry for Tight Junction Components Under ER Stress

Immunohistochemistry was also performed in monolayered cells to detect the alterations of ZO-1, occludin, and claudin-1 expressions under ER stress for 48 hours (Figure 4). The staining of the junctions for each peptide was weak in the controls. ER stress induced by TM or TG increased the intensity of staining for ZO-1, occludin, and claudin-1 to higher levels than that of the control (Figure 4). Throughout the experiments, cell death was not detected.

## Measurement of TER

The cells grown under for 48 hours of ER stress induced by TM or TG had higher TER values than that of the control (TM, 2.2-fold, $P<0.001$; TG, 1.7-fold, $P<0.001$, Figure 5). This significant increase in the TER values indicated that the permeability through the monolayer of RPE cells was reduced under ER stress.

## DISCUSSION

ER stress has been suggested to be the cause of a broad range of diseases involving the accumulation of unfolded or misfolded proteins in the ER.[7-10] Several studies have shown that ER stress up-regulates the expression of inflammatory cytokines, such as tumor necrosis factor (TNF)-α, in different cultured cell lines.[5,24] Thus, ER stress would possibly be a cause of inflammation.[6,24]

The integrity of the intercellular junctions of RPE cells can be affected by several pro-inflammatory cytokines, e.g., TNF-α, interleukin-1β, hepatocyte growth factor, and placental growth factor-1.[25-28] These cytokines decrease the TER, increase the permeability, and alter the expression or content of the tight junction molecules.[25-28] The expression of VEGF mRNA in ARPE-19 cells up-regulated by ER stress has been reported.[12] VEGF has been reported to decrease the expression and the function of tight junctions.[29] The tight junction proteins occludin and claudin-1 could not be detected, and ZO-1 was weakly affected in the microvascular retinal endothelial cells exposure to VEGF165 [29] In addition, exposure of ARPE-19 cells to VEGF induced a significant drop in the TER.[30]

RIGHTSLINK




FIGURE 3 Expression of tight junctions under ER stress. (A) mRNA expressions of tight junction components induced by TM. The mRNA expression of ZO-1 is increased under ER stress induced by TM, but the difference was not significant. However, the mRNA expressions of occludin and claudin-1 are significantly up-regulated by TM treatment after 6, 12, 24 and 48 hours compared to that at the initial levels. (B) mRNA expressions of tight junction induced by TG. The mRNA expression of ZO-1 is significantly up-regulated under ER stress induced by TG after 24 and 48 hours. The expressions of occludin and claudin-1 are also significantly increased after 12, 24 and 48 hours compared to that at the initial levels. (C) Results of Western blot. Protein expressions of ZO-1, occludin, and claudin-1 are increased by TG and TM. (D) Results of densitometric analyses. Protein expression of ZO-1 under ER stress is significantly increased by TG but not significant by TM. The protein levels of occludin and claudin-1 under ER stress are significantly increased compared to that of the control. Data are presented as the means ± SEMs. $* = P < 0.05$, $** = P < 0.01$, $*** = P < 0.001$.

For personal use only.

© 2011 Informa Healthcare USA, Inc.

RIGHTSLINK




FIGURE 4 Immunohistochemistry for tight junction components under ER stress. (A, B and C) Immunoreactivity for ZO-1, (D, E, and F) occludin, and (G, H, and I) claudin-1. Immunohistochemistry was performed in grown monolayer cells to detect the alterations of the tight junction components under ER stress. Junctional staining of each peptide, ZO-1, occludin, and claudin-1 is weakly observed in the controls. Under ER stress-induced by TM or TG, the staining is stronger than that of the controls.




FIGURE 5 Measurement of transepithelial resistance (TER) in ARPE 19 cells under ER stress. TER is enhanced by ER stress induced by TM or TG after 48 hours. Data are presented as the means ± SEMs. *** = $P < 0.001$.

Surprisingly, we found that the expression of the tight junctions was increased by ER stress, i.e. the ER stress-induced by TM and TG led to an up-regulation of the expression of the mRNA of ZO-1, occludin, and claudin-1. Our immunohistochemical experiments also showed that the junctional staining of each peptide appeared to be stronger under ER stress than that of the control. These results support the increased TER under ER stress. It appears that under our conditions, ER stress strengthens rather than weakens the tight junction of ARPE-19 cells. Our results are not consistent with the results of earlier studies which reported that VEGF decreased the expression and the function of tight junctions.[29,30]

Several reasons have been advanced for the increase of TER under ER stress. Abonczy et al. reported that exposure of ARPE-19 cells to 10 ng/ml VEGF165 induced a significant drop in the TER.[30] However in our study, the concentration of VEGF165 was very low, at about 1800 pg/ml, in the apical chamber medium, and it was not significantly different from that of the control after 48 hours exposure to TM and TG. While the basolateral secretion of VEGF165 was significantly increased compared to that of the control, TER was unaffected by the basolateral secretion of VEGF165 because, the expression of VEGF-R2 was limited to the apical surface.[30] Thus, it is quite possible that the increase of TER was not affected by this level of VEGF165 concentration observed in our study.

Mendes et al. reported that mild ER stress protected retinal cells from apoptosis.[31] The ER stress-mediated protective effect can be a preconditioning or an adaptive stress response, termed hormesis.[31] Lehotsky et al. demonstrated that preconditioning pre-ischemia underlies its neuroprotective effect, and it acts by attenuating the ER stress response after acute ischemic/reperfusion insult.[32] Furthermore, it has been reported that the protective effect of ER stress preconditioning against retinal endothelial inflammation is likely through the activation of XBP1-mediated UPR and inhibition of NF-κB activation.[33] It is possible that the concentration of TM and TG used in our study induced mild ER stress, because the ER stress increased the mRNA and protein expressions of Bip and the protein of ATF6. The transcriptions of Bip and ATF6 are classic markers of UPR activation in mammalian cells.[34,35] UPR involves an initial inhibition of translation to prevent further accumulation of misfolded proteins, an up-regulation of chaperone genes to further facilitate protein folding, and activation of the ER-associated degradation system, which retro-translocates misfolded proteins from the ER for proteasome-dependent degradation.[36] Bip acts as an ER-resident molecular chaperone induced by ER stress, and this protein refolds the unfolded proteins, thereby maintaining the homeostasis in the ER.[37] ATF6 serves as a proximal sensor that regulates components that up-regulate the capacity of ER to synthesize new proteins and degrade misfolded proteins.[35]

In contrast, it has been reported that human caspase-4, which is a resident of the ER, induces apoptosis under ER stress, and CHOP, which is present in the cytosol under normal conditions and translocates to nucleus during ER stress, is a modulator of ER stress-induced cell death.[35,38,39] Our results showed that ER stress-induced a strong up-regulation of the mRNA and protein of CHOP. Moreover, the expression of cleaved caspase-4 protein was significantly increased. Mild up-regulation of Bip and ATF6 induced by TM and TG may elicit both adaptive UPR and terminal UPR. Only a limited number of studies have been done to determine whether UPR switches protective effect to apoptosis.

Curr Eye Res Downloaded from informahealthcare.com by Maruzen Co Ltd on 05/01/12
For personal use only.

RIGHTSLINK

For personal use only.

ER stress induces the oxidative stress through both inducible nitric oxide synthase (iNOS) dependent and independent pathway.[40] The low levels of reactive oxygen species (ROS) maintain proper cell function and excess levels of ROS can overwhelm the anti-oxidant systems.[41] Furthermore, ROS have been implicated in the preconditioning phenomenon.[42,43] Ravati et al. demonstrated that preconditioning stimulated by moderate levels of ROS protect cultured neurons.[43] Therefore, it is possible that our finding, the up-regulation of tight junctions and the increase of TER under ER stress, might have resulted from low levels of ROS and/or pro-survival pathway induced by ER stress. Furthermore studies on P-I3k-Akt or ERK as well as the contribution of bcl-2 family members including the levels of the Bcl-2/Bax ratio may reveal other pro-survival pathways.

Recent studies suggest a role for ER stress in neurodegenerative diseases, e.g. AMD.[10,13,44] Druzen, deposits of neutral lipid, is the clinical sign of AMD.[45] Sarks et al. reported that drusen localized between the RPE and the inner collagen layer of the Bruch's membrane.[46] Recently, new evidence has indicated that in AMD, substructural elements within drusen contain amyloid β (Aβ).[47,48] ER stress has been reported to be one of the causative factors for the accumulation of Aβ.[49,50] Koyama et al. reported that ER stress-induced Aβ accumulation in ARPE-19 cells.[12] Aβ accumulation increases the expression of VEGF, which plays an important role in ocular angiogenesis, including choroidal neovascularization. In addition, Aβ reduced the expression of occludin, markedly decreased the attachment capacity, and abolished the selectivity of RPE cell transepithelial permeability.[51] Thus, it is possible that ER stress and Aβ accumulation weaken the Bruch's membrane by inducing the inflammatory cytokines and VEGF.

Pigment epithelium detachment (PED) is a pathogenic status often observed in patients with AMD.[52] PED occurs between the basement membrane of the RPE cells and the inner collagen layer of the Bruch's membrane. However, the mechanism how PED occurs has not been determined. Our findings cannot be easily applied to clinical practice because, the AMD has many elements such as cytokines, growth factors, and ROS that could be involved in the integrity of tight junction. However, together with the results of earlier studies, a weakening of the basement membrane of RPE cells to inner collagen layer of the Bruch's membrane with accumulation of Aβ in drusen and up-regulated expression of tight junctions in RPE under ER stress may explain the development of PED in patients with AMD (Figure 6).

Proteome analysis of human retinas with AMD and murine models of retinal degeneration found altered expression of molecular chaperones, a diverse group of proteins found in high concentrations in the ER.[53,54] The molecular chaperones help prevent protein aggregation




FIGURE 6 Diagram of how ER stress might affect the pigment epithelial detachment (PED). ER stress weakens the Bruch's membrane with accumulation of amyloid β in druzen, and the up-regulation in the expression of tight junctions in RPE may induce PED in patients with AMD. ICL, inner collagen layer of the Bruch's membrane; OCL, outer collagen layer of the Bruch's membrane.

by encouraging unfolded proteins to a folding competent state and also function as a component of the ER-specific protein-degrading apparatus to eliminate misfolded proteins.[36,55] These and other data indicate that the pathogenesis of AMD may be mediated, at least in part, by ER stress. Because Bip was increased in this study, ER stress-mediated molecular chaperones may up-regulate tight junctions and increase TER in RPE cells and may accompany the AMD.

In conclusion, increased expressions of tight junctions by TM or TG exposure in ARPE-19 cells indicate that ER stress can alter the function of RPE cells and may be involved in the pathogenesis of AMD.

*Declaration of interest*: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

## REFERENCES

[1] Chevet E, Cameron PH, Pelletier MF, Thomas DY, Bergeron JJ. The endoplasmic reticulum: Integration of protein folding, quality control, signaling and degradation. *Curr Opin Struct Biol* 2001;11:120–124.

[2] Görlach A, Klappa P, Kietzmann T. The endoplasmic reticulum: Folding, calcium homeostasis, signaling, and redox control. *Antioxid Redox Signal* 2006;8:1391–1418.

[3] Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. *Nat Rev Mol Cell Biol* 2007;8:519–529.

© 2011 Informa Healthcare USA, Inc.

RIGHTSLINK

[4] Gargalovic PS, Gharavi NM, Clark MJ et al. The unfolded protein response is an important regulator of inflammatory genes in endothelial cells. *Arterioscler Thromb Vasc Biol* 2006;26:2490–2496.
[5] Hu P, Han Z, Couvillon AD, Kaufman RJ, Exton JH. Autocrine tumor necrosis factor α links endoplasmic reticulum stress to the membrane death receptor pathway through IRE1α-mediated NF-κB activation and down-regulation of TRAF2 expression. *Mol Cell Biol* 2006;26:3071–3084.
[6] Zhang K, Kaufman RJ. From endoplasmic-reticulum stress to the inflammatory response. *Nature* 2008;454:455–462.
[7] Tajiri S, Oyadomari S, Yano S et al. Ischemia-induced neuronal cell death is mediated by the endoplasmic reticulum stress pathway involving CHOP. *Cell Death Differ* 2004;11:403–415.
[8] Oyadomari S, Takeda K, Takiguchi M et al. Nitric oxide-induced apoptosis in pancreatic β cells is mediated by the endoplasmic reticulum stress pathway. *Proc Natl Acad Sci USA* 2001;98:10845–10850.
[9] Salminen A, Kauppinen A, Suuronen T, Kaarniranta K, Ojala J. ER stress in Alzheimer's disease: A novel neuronal trigger for inflammation and Alzheimer's pathology. *J Neuroinflammation* 2009;6:41.
[10] Lindholm D, Wootz H, Korhonen L. ER stress and neurodegenerative diseases. *Cell Death Differ* 2006;13:385–392.
[11] Li J, Wang JJ, Yu Q, Wang M, Zhang SX. Endoplasmic reticulum stress is implicated in retinal inflammation and diabetic retinopathy. *FEBS Lett* 2009;583:1521–1527.
[12] Koyama Y, Matsuzaki S, Gomi F et al. Induction of amyloid β accumulation by ER calcium disruption and resultant up-regulation of angiogenic factors in ARPE-19 cells. *Invest Ophthalmol Vis Sci* 2008;49:2376–2383.
[13] Salminen A, Kauppinen A, Hyttinen JM, Toropainen E, Kaarniranta K. Endoplasmic reticulum stress in age-related macular degeneration: Trigger for neovascularization. *Mol Med* 2010;16:535–542.
[14] Strauss O. The retinal pigment epithelium in visual function. *Physiol Rev* 2005;85:845–881.
[15] Erickson KK, Sundstrom JM, Antonetti DA. Vascular permeability in ocular disease and the role of tight junctions. *Angiogenesis* 2007;10:103–117.
[16] González-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight junction proteins. *Prog Biophys Mol Biol* 2003;81:1–44.
[17] Mahoney WC, Duksin D. Biological activities of the two major components of tunicamycin. *J Biol Chem* 1979;254:6572–6576.
[18] Olden K, Pratt RM, Jaworski C, Yamada KM. Evidence for role of glycoprotein carbohydrates in membrane transport: Specific inhibition by tunicamycin. *Proc Natl Acad Sci USA* 1979;76:791–795.
[19] Patil C, Walter P. Intracellular signaling from the endoplasmic reticulum to the nucleus: The unfolded protein response in yeast and mammals. *Curr Opin Cell Biol* 2001;13:349–355.
[20] Treiman M, Caspersen C, Christensen SB. A tool coming of age: Thapsigargin as an inhibitor of sarco-endoplasmic reticulum Ca(2+)-ATPases. *Trends Pharmacol Sci* 1998;19: 131–135.
[21] Jackson TR, Patterson SI, Thastrup O, Hanley MR. A novel tumour promoter, thapsigargin, transiently increases cytoplasmic free $Ca^{2+}$ without generation of inositol phosphates in NG115-401L neuronal cells. *Biochem J* 1988;253:81–86.
[22] Shimazawa M, Inokuchi Y, Ito Y et al. Involvement of ER stress in retinal cell death. *Mol Vis* 2007;13:578–587.
[23] Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. *Cell Death Differ* 2004;11:381–389.
[24] Gargalovic PS, Imura M, Zhang B et al. Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. *Proc Natl Acad Sci USA* 2006;103:12741–12746.
[25] Abe T, Sugano E, Saigo Y, Tamai M. Interleukin-1β and barrier function of retinal pigment epithelial cells (ARPE-19): Aberrant expression of junctional complex molecules. *Invest Ophthalmol Vis Sci* 2003;44:4097–4104.
[26] Jin M, Barron E, He S, Ryan SJ, Hinton DR. Regulation of RPE intercellular junction integrity and function by hepatocyte growth factor. *Invest Ophthalmol Vis Sci* 2002;43:2782–2790.
[27] Miyamoto N, de Kozak Y, Jeanny JC et al. Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: Potential implication in the pathogenesis of diabetic retinopathy. *Diabetologia* 2007;50:461–470.
[28] Zech JC, Pouvreau I, Cotinet A, Goureau O, Le Varlet B, de Kozak Y. Effect of cytokines and nitric oxide on tight junctions in cultured rat retinal pigment epithelium. *Invest Ophthalmol Vis Sci* 1998;39:1600–1608.
[29] Deissler H, Deissler H, Lang S, Lang GE. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (lucentis) in microvascular retinal endothelial cells. *Br J Ophthalmol* 2008;92:839–843.
[30] Ablonczy Z, Crosson CE. VEGF modulation of retinal pigment epithelium resistance. *Exp Eye Res* 2007;85:762–771.
[31] Mendes CS, Levet C, Chatelain G et al. ER stress protects from retinal degeneration. *EMBO J* 2009;28:1296–1307.
[32] Lehotský J, Urban P, Pavlíková M, Tatarková Z, Kaminska B, Kaplán P. Molecular mechanisms leading to neuroprotection/ischemic tolerance: Effect of preconditioning on the stress reaction of endoplasmic reticulum. *Cell Mol Neurobiol* 2009;29:917–925.
[33] Li J, Wang JJ, Zhang SX. Preconditioning with endoplasmic reticulum stress mitigates retinal endothelial inflammation via activation of X-box binding protein 1. *J Biol Chem* 2011;286:4912–4921.
[34] Misra UK, Pizzo SV. Up-regulation of GRP78 and antiapoptotic signaling in murine peritoneal macrophages exposed to insulin. *J Leukoc Biol* 2005;78:187–194.
[35] Rao RV, Ellerby HM, Bredesen DE. Coupling endoplasmic reticulum stress to the cell death program. *Cell Death Differ* 2004;11:372–380.
[36] Lai E, Teodoro T, Volchuk A. Endoplasmic reticulum stress: Signaling the unfolded protein response. *Physiology (Bethesda)* 2007;22:193–201.
[37] Ma Y, Hendershot LM. ER chaperone functions during normal and stress conditions. *J Chem Neuroanat* 2004;28:51–65.
[38] Kim SJ, Zhang Z, Hitomi E, Lee YC, Mukherjee AB. Endoplasmic reticulum stress-induced caspase-4 activation mediates apoptosis and neurodegeneration in INCL. *Hum Mol Genet* 2006;15:1826–1834.
[39] Dasari B, Prasanthi JR, Marwarha G, Singh BB, Ghribi O. The oxysterol 27-hydroxycholesterol increases β-amyloid and oxidative stress in retinal pigment epithelial cells. *BMC Ophthalmol* 2010;10:22.
[40] Hsieh YH, Su IJ, Lei HY, Lai MD, Chang WW, Huang W. Differential endoplasmic reticulum stress signaling pathways mediated by iNOS. *Biochem Biophys Res Commun* 2007;359:643–648.
[41] Busija DW, Gaspar T, Domoki F, Katakam PV, Bari F. Mitochondrial-mediated suppression of ROS production upon exposure of neurons to lethal stress: Mitochondrial targeted preconditioning. *Adv Drug Deliv Rev* 2008;60:1471–1477.
[42] Correia SC, Carvalho C, Cardoso S et al. Mitochondrial preconditioning: A potential neuroprotective strategy. *Front Aging Neurosci* 2010;2:138.
[43] Ravati A, Ahlemeyer B, Becker A, Krieglstein J. Preconditioning-induced neuroprotection is mediated by reactive oxygen species. *Brain Res* 2000;866:23–32.
[44] Meriin AB, Sherman MY. Role of molecular chaperones in neurodegenerative disorders. *Int J Hyperthermia* 2005;21:403–419.
[45] Gass JD. Drusen and disciform macular detachment and degeneration. *Trans Am Ophthalmol Soc* 1972;70:409–436.

Curr Eye Res Downloaded from informahealthcare.com by Maruzen Co Ltd on 05/01/12
For personal use only.

RIGHTS LINK

[46] Sarks S, Cherepanoff S, Killingsworth M, Sarks J. Relationship of basal laminar deposit and membranous debris to the clinical presentation of early age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2007;48:968–977.
[47] Dentchev T, Milam AH, Lee VM, Trojanowski JQ, Dunaief JL. Amyloid-β is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. *Mol Vis* 2003;9:184–190.
[48] Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johnson LV. Characterization of β amyloid assemblies in drusen: The deposits associated with aging and age-related macular degeneration. *Exp Eye Res* 2004;78: 243–256.
[49] Sato N, Imaizumi K, Manabe T et al. Increased production of β-amyloid and vulnerability to endoplasmic reticulum stress by an aberrant spliced form of presenilin 2. *J Biol Chem* 2001;276:2108–2114.
[50] Katayama T, Imaizumi K, Manabe T, Hitomi J, Kudo T, Tohyama M. Induction of neuronal death by ER stress in Alzheimer's disease. *J Chem Neuroanat* 2004;28:67–78.
[51] Bruban J, Glotin AL, Dinet V et al. Amyloid-β(1–42) alters structure and function of retinal pigmented epithelial cells. *Aging Cell* 2009;8:162–177.
[52] Zayit-Soudry S, Moroz I, Loewenstein A. Retinal pigment epithelial detachment. *Surv Ophthalmol* 2007;52:227–243.
[53] Ethen CM, Reilly C, Feng X, Olsen TW, Ferrington DA. The proteome of central and peripheral retina with progression of age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2006;47:2280–2290.
[54] Tuo J, Bojanowski CM, Zhou M et al. Murine ccl2/cx3cr1 deficiency results in retinal lesions mimicking human age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2007;48:3827–3836.
[55] Bukau B, Weissman J, Horwich A. Molecular chaperones and protein quality control. *Cell* 2006;125:443–451.

For personal use only.

© 2011 Informa Healthcare USA, Inc.

RIGHTSLINK